<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35754054</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis.</ArticleTitle><Pagination><StartPage>209</StartPage><MedlinePgn>209</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-022-02411-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">The time of survival in patients with amyotrophic lateral sclerosis (ALS) varies greatly, and the genetic factors that contribute to the survival of ALS are not well studied. There is a lack of a comprehensive study to elucidate the role of genetic factors in the survival of ALS.</AbstractText><AbstractText Label="METHODS">The published studies were systematically searched and obtained from PubMed, EMBASE, and the Cochrane Library without any language restrictions from inception to Oct 27, 2021. A network meta-analysis for ALS causative/risk genes and a systematic review and pairwise meta-analysis for other genetic modifiers were conducted. The PROSPERO registration number: CRD42022311646.</AbstractText><AbstractText Label="RESULTS">A total of 29,764 potentially relevant references were identified, and 71 papers were eligible for analysis based on pre-decided criteria, including 35 articles in network meta-analysis for 9 ALS causative/risk genes, 17 articles in pairwise meta-analysis for four genetic modifiers, and 19 articles described in the systematic review. Variants in three genes, including ATXN2 (HR: 3.6), C9orf72 (HR: 1.6), and FUS (HR:1.8), were associated with short survival of ALS, but such association was not identified in SOD1, TARDBP, TBK1, NEK1, UBQLN2, and CCNF. In addition, UNC13A rs12608932 CC genotype and ZNF521B rs2275294 C allele also caused a shorter survival of ALS; however, APOE &#x3b5;4 allele and KIFAP3 rs1541160 did not be found to have any effect on the survival of ALS.</AbstractText><AbstractText Label="CONCLUSIONS">Our study summarized and contrasted evidence for prognostic genetic factors in ALS and would help to understand ALS pathogenesis and guide clinical trials and drug development.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Wei-Ming</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Neurodegenerative Disorders, Institute of Inflammation and Immunology (III), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Rare Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Xiao-Jing</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Neurodegenerative Disorders, Institute of Inflammation and Immunology (III), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Rare Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Qing-Qing</ForeName><Initials>QQ</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Neurodegenerative Disorders, Institute of Inflammation and Immunology (III), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Rare Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Neurodegenerative Disorders, Institute of Inflammation and Immunology (III), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Rare Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Dazhou Central Hospital, Dazhou, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Hui-Fang</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Neurodegenerative Disorders, Institute of Inflammation and Immunology (III), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Rare Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong-Ping</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. yongping.chen@wchscu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Neurodegenerative Disorders, Institute of Inflammation and Immunology (III), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. yongping.chen@wchscu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Rare Diseases, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. yongping.chen@wchscu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071183">Autophagy-Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C405662">UBQLN2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071183" MajorTopicYN="N">Autophagy-Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071076" MajorTopicYN="N">Network Meta-Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Genes</Keyword><Keyword MajorTopicYN="N">Modifier</Keyword><Keyword MajorTopicYN="N">Survival</Keyword><Keyword MajorTopicYN="N">Variants</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>26</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35754054</ArticleId><ArticleId IdType="pmc">PMC9235235</ArticleId><ArticleId IdType="doi">10.1186/s12916-022-02411-3</ArticleId><ArticleId IdType="pii">10.1186/s12916-022-02411-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, Chinea A. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6(1):171. doi: 10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, McLaughlin R, Hardiman O. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(6):623&#x2013;627. doi: 10.1136/jnnp.2010.224501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.224501</ArticleId><ArticleId IdType="pubmed">21047878</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat. 2012;33(9):1345&#x2013;1351. doi: 10.1002/humu.22157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22157</ArticleId><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Su WM, Cheng YF, Jiang Z, Duan QQ, Yang TM, Shang HF, Chen YP. Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis. EBioMedicine. 2021;74:103732. doi: 10.1016/j.ebiom.2021.103732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103732</ArticleId><ArticleId IdType="pmc">PMC8646173</ArticleId><ArticleId IdType="pubmed">34864363</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PW, van Rheenen W, Koppers M, Pasterkamp RJ, van Es MA, Schelhaas HJ, de Visser M, Robberecht W, Van Damme P, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(3):630.e633&#x2013;630.e638. doi: 10.1016/j.neurobiolaging.2011.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.029</ArticleId><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I, Lin K, Tiloca C, Rooney J, Gellera C, Diekstra FP, Ratti A, Shatunov A, van Es MA, Proitsi P, et al. Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurol. 2016;73(7):812&#x2013;820. doi: 10.1001/jamaneurol.2016.1114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.1114</ArticleId><ArticleId IdType="pmc">PMC5556366</ArticleId><ArticleId IdType="pubmed">27244217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Restagno G, Brunetti M, Ossola I, Barberis M, Ferrucci L, Canosa A, Manera U, Moglia C, et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiol Aging. 2013;34(1):357.e351&#x2013;357.e355. doi: 10.1016/j.neurobiolaging.2012.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.07.016</ArticleId><ArticleId IdType="pmc">PMC3483408</ArticleId><ArticleId IdType="pubmed">22921269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, Conforti FL, Zollino M, Mora G, Monsurr&#xf2; MR, Volanti P, Marinou K, Salvi F, Corbo M, Giannini F, et al. C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiol Aging. 2012;33(8):1848.e1815&#x2013;1848.e1820. doi: 10.1016/j.neurobiolaging.2012.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.02.011</ArticleId><ArticleId IdType="pmc">PMC3372681</ArticleId><ArticleId IdType="pubmed">22418734</ArticleId></ArticleIdList></Reference><Reference><Citation>Miltenberger-Miltenyi G, Concei&#xe7;&#xe3;o VA, Gromicho M, Pronto-Laborinho AC, Pinto S, Andersen PM, de Carvalho M. C9orf72 expansion is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(1):118&#x2013;120. doi: 10.1136/jnnp-2018-318032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318032</ArticleId><ArticleId IdType="pubmed">29661924</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;bers A, Just W, Rosenbohm A, M&#xfc;ller K, Marroquin N, Goebel I, H&#xf6;gel J, Thiele H, Altm&#xfc;ller J, N&#xfc;rnberg P, et al. De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients. Neurobiol Aging. 2015;36(11):3117.e3111&#x2013;3117.e3116. doi: 10.1016/j.neurobiolaging.2015.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.005</ArticleId><ArticleId IdType="pubmed">26362943</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Valdmanis P, Millecamps S, Lionnet C, Blasco H, Mouzat K, Daoud H, Belzil V, Morales R, Pageot N, et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology. 2012;78(19):1519&#x2013;1526. doi: 10.1212/WNL.0b013e3182553c88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182553c88</ArticleId><ArticleId IdType="pubmed">22539580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YP, Yu SH, Wei QQ, Cao B, Gu XJ, Chen XP, et al. Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population. J Med Genet. 2021. 10.1136/jmedgenet-2021-107965.</Citation><ArticleIdList><ArticleId IdType="pubmed">34544842</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, Salanti G. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17(2):157&#x2013;173. doi: 10.1016/j.jval.2014.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2014.01.004</ArticleId><ArticleId IdType="pubmed">24636374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777&#x2013;784. doi: 10.7326/M14-2385.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-2385</ArticleId><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, Group P Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12(11):1059&#x2013;1067. doi: 10.1016/S1474-4422(13)70221-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70221-7</ArticleId><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-8-16</ArticleId><ArticleId IdType="pmc">PMC1920534</ArticleId><ArticleId IdType="pubmed">17555582</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10:54. doi: 10.1186/1471-2288-10-54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-10-54</ArticleId><ArticleId IdType="pmc">PMC2906500</ArticleId><ArticleId IdType="pubmed">20537177</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603&#x2013;605. doi: 10.1007/s10654-010-9491-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-010-9491-z</ArticleId><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088&#x2013;1101. doi: 10.2307/2533446.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2533446</ArticleId><ArticleId IdType="pubmed">7786990</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7-8):932&#x2013;944. doi: 10.1002/sim.3767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3767</ArticleId><ArticleId IdType="pubmed">20213715</ArticleId></ArticleIdList></Reference><Reference><Citation>Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163&#x2013;171. doi: 10.1016/j.jclinepi.2010.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.03.016</ArticleId><ArticleId IdType="pubmed">20688472</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghero G, Pugliatti M, Marrosu F, Marrosu MG, Murru MR, Floris G, Cannas A, Parish LD, Cau TB, Loi D, et al. ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. Neurobiol Aging. 2015;36(10):2906.e2901&#x2013;2906.e2905. doi: 10.1016/j.neurobiolaging.2015.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.06.013</ArticleId><ArticleId IdType="pmc">PMC5193218</ArticleId><ArticleId IdType="pubmed">26208502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, Canosa A, Brunetti M, Barberis M, Restagno G, Conte A, Bisogni G, Marangi G, et al. ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology. 2015;84(3):251&#x2013;258. doi: 10.1212/WNL.0000000000001159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001159</ArticleId><ArticleId IdType="pubmed">25527265</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11(3):232&#x2013;240. doi: 10.1016/S1474-4422(12)70014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Corrado L, Castellotti B, Del Bo R, Fogh I, Cereda C, Tiloca C, D'Ascenzo C, Bagarotti A, Pensato V, et al. C9ORF72 repeat expansion in a large Italian ALS cohort: evidence of a founder effect. Neurobiol Aging. 2012;33(10):2528.e2527&#x2013;2528.e2514. doi: 10.1016/j.neurobiolaging.2012.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.06.008</ArticleId><ArticleId IdType="pubmed">22766072</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van Blitterswijk M, Huisman MH, Vlam L, van Doormaal PT, Seelen M, Medic J, Dooijes D, de Visser M, van der Kooi AJ, et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology. 2012;79(9):878&#x2013;882. doi: 10.1212/WNL.0b013e3182661d14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182661d14</ArticleId><ArticleId IdType="pubmed">22843265</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Boillee S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M, Moigneu C, Vandenberghe N, Danel-Brunaud V, Corcia P, et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet. 2012;49(4):258&#x2013;263. doi: 10.1136/jmedgenet-2011-100699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2011-100699</ArticleId><ArticleId IdType="pubmed">22499346</ArticleId></ArticleIdList></Reference><Reference><Citation>Debray S, Race V, Crabb&#xe9; V, Herdewyn S, Matthijs G, Goris A, Dubois B, Thijs V, Robberecht W, Van Damme P. Frequency of C9orf72 repeat expansions in amyotrophic lateral sclerosis: a Belgian cohort study. Neurobiol Aging. 2013;34(12):2890.e2897&#x2013;2890.e2812. doi: 10.1016/j.neurobiolaging.2013.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.06.009</ArticleId><ArticleId IdType="pubmed">23870417</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Redondo A, Dols-Icardo O, Rojas-Garc&#xed;a R, Esteban-P&#xe9;rez J, Cordero-V&#xe1;zquez P, Mu&#xf1;oz-Blanco JL, Catalina I, Gonz&#xe1;lez-Mu&#xf1;oz M, Varona L, Sarasola E, et al. Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. Hum Mutat. 2013;34(1):79&#x2013;82. doi: 10.1002/humu.22211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22211</ArticleId><ArticleId IdType="pubmed">22936364</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, Toledo JB, Boller A, Bekisz J, Chandrasekaran K, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(2):163&#x2013;169. doi: 10.1136/jnnp-2012-303507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303507</ArticleId><ArticleId IdType="pmc">PMC3543474</ArticleId><ArticleId IdType="pubmed">23117491</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P, Robberecht W, Van Damme P. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71(5):553&#x2013;561. doi: 10.1001/jamaneurol.2014.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, et al. Influence of cigarette smoking on ALS outcome: a population-based study. J Neurol Neurosurg Psychiatry. 2016;87(11):1229&#x2013;1233. doi: 10.1136/jnnp-2016-313793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313793</ArticleId><ArticleId IdType="pubmed">27656044</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Fournier C, Li Y, Polak M, Shaw L, Landers JE, Hu W, Gearing M, Glass JD. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology. 2016;87(10):1024&#x2013;1030. doi: 10.1212/WNL.0000000000003067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003067</ArticleId><ArticleId IdType="pmc">PMC5027809</ArticleId><ArticleId IdType="pubmed">27488601</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Daughrity LM, Heckman MG, Diehl NN, Wuu J, Miller TM, Pastor P, Trojanowski JQ, Grossman M, Berry JD, et al. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann Neurol. 2017;82(1):139&#x2013;146. doi: 10.1002/ana.24980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Reniers W, Schrooten M, Claeys KG, Tilkin P, D'Hondt A, Van Reijen D, Couwelier G, Lamaire N, Robberecht W, Fieuws S, et al. Prognostic value of clinical and electrodiagnostic parameters at time of diagnosis in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5-6):341&#x2013;350. doi: 10.1080/21678421.2017.1288254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1288254</ArticleId><ArticleId IdType="pubmed">28631957</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammack AJ, Atassi N, Hyman T, van den Berg LH, Harms M, Baloh RH, Brown RH, van Es MA, Veldink JH, de Vries BS, et al. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019;93(17):e1605&#x2013;e1617. doi: 10.1212/WNL.0000000000008359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008359</ArticleId><ArticleId IdType="pmc">PMC6946465</ArticleId><ArticleId IdType="pubmed">31578300</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Murray D, Campion A, Moloney H, Tattersall R, Doherty M, Hammond M, Heverin M, McLaughlin R, Hardiman O. The C9orf72 expansion is associated with accelerated respiratory function decline in a large Amyotrophic Lateral Sclerosis cohort. HRB Open Res. 2019;2:23. doi: 10.12688/hrbopenres.12940.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/hrbopenres.12940.1</ArticleId><ArticleId IdType="pmc">PMC7140774</ArticleId><ArticleId IdType="pubmed">32296747</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Ferro C, et al. Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Front Neurosci. 2019;13:485. doi: 10.3389/fnins.2019.00485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00485</ArticleId><ArticleId IdType="pmc">PMC6534038</ArticleId><ArticleId IdType="pubmed">31156370</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R, Swenson A, Ravits J, Jackson C, Burns TM, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):e59&#x2013;e69. doi: 10.1212/WNL.0000000000009559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Lunetta C, Tarlarini C, Mosca L, Chio A, Van Damme P, Poesen K. Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(4):436&#x2013;437. doi: 10.1136/jnnp-2019-322309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322309</ArticleId><ArticleId IdType="pubmed">32029541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kl&#xe4;ppe U, Chamoun S, Shen Q, Finn A, Evertsson B, Zetterberg H, et al. Cardiac troponin T is elevated and increases longitudinally in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1-2):58&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">34151677</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, Lombardi V, Lu CH, Yildiz O, Fratta P, Isaacs A, Bobeva Y, Wuu J, Benatar M, Malaspina A. Humoral response to neurofilaments and dipeptide repeats in ALS progression. Ann Clin Transl Neurol. 2021;8(9):1831&#x2013;1844. doi: 10.1002/acn3.51428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51428</ArticleId><ArticleId IdType="pmc">PMC8419401</ArticleId><ArticleId IdType="pubmed">34318620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, Schoenfeld DA, Hosler BA, Horvitz HR, Brown RH. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41(2):210&#x2013;221. doi: 10.1002/ana.410410212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410212</ArticleId><ArticleId IdType="pubmed">9029070</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Li X, Sun Y, Yu X, Wang Y, Liu N, et al. Genotype-phenotype correlations in a chinese population with familial amyotrophic lateral sclerosis. Neurol Res. 2022;44(3):206&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">34431456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Conte A, Zollino M, Luigetti M, Del Grande A, Marangi G, Romano A, Marcaccio A, Meleo E, Bisogni G, et al. Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology. 2012;79(1):66&#x2013;72. doi: 10.1212/WNL.0b013e31825dceca.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31825dceca</ArticleId><ArticleId IdType="pubmed">22722621</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghero G, Pugliatti M, Marrosu F, Marrosu MG, Murru MR, Floris G, Cannas A, Parish LD, Occhineri P, Cau TB, et al. Genetic architecture of ALS in Sardinia. Neurobiol Aging. 2014;35(12):2882.e2887&#x2013;2882.e2812. doi: 10.1016/j.neurobiolaging.2014.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.012</ArticleId><ArticleId IdType="pmc">PMC4252367</ArticleId><ArticleId IdType="pubmed">25123918</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, Camuzat A, Guillot-No&#xeb;l L, Russaouen O, Bruneteau G, Pradat PF, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet. 2010;47(8):554&#x2013;560. doi: 10.1136/jmg.2010.077180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2010.077180</ArticleId><ArticleId IdType="pubmed">20577002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Borghero G, Restagno G, Mora G, Drepper C, Traynor BJ, Sendtner M, Brunetti M, Ossola I, Calvo A, et al. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain. 2012;135(Pt 3):784&#x2013;793. doi: 10.1093/brain/awr366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr366</ArticleId><ArticleId IdType="pmc">PMC3286333</ArticleId><ArticleId IdType="pubmed">22366794</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP, Williams KL, Fifita JA, Tarr IS, O'Connor J, Rowe DB, Nicholson GA, Blair IP. The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet. 2017;92(3):259&#x2013;266. doi: 10.1111/cge.12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12973</ArticleId><ArticleId IdType="pubmed">28105640</ArticleId></ArticleIdList></Reference><Reference><Citation>Govaarts R, Beeldman E, Kampelmacher MJ, van Tol MJ, van den Berg LH, van der Kooi AJ, Wijkstra PJ, Zijnen-Suyker M, Cobben NA, Schmand BA, et al. The frontotemporal syndrome of ALS is associated with poor survival. J Neurol. 2016;263(12):2476&#x2013;2483. doi: 10.1007/s00415-016-8290-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8290-1</ArticleId><ArticleId IdType="pmc">PMC5110703</ArticleId><ArticleId IdType="pubmed">27671483</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand D, Polak M, Glass JD, Fournier CN. Comparison of Phenotypic Characteristics and Prognosis Between Black and White Patients in a Tertiary ALS Clinic. Neurology. 2021;96(6):e840&#x2013;e844. doi: 10.1212/WNL.0000000000011396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011396</ArticleId><ArticleId IdType="pubmed">33372030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammar Al-Chalabi ZEE, Bakker MC, et al. Association of apolipoprotein E4 allele with bulbar-onset motor neuron disease. Lancet. 1996;347:159&#x2013;160. doi: 10.1016/S0140-6736(96)90343-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)90343-8</ArticleId><ArticleId IdType="pubmed">8544551</ArticleId></ArticleIdList></Reference><Reference><Citation>Drory VE, Birnbaum M, Korczyn AD, Chapman J. Association of APOE epsilon4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci. 2001;190(1-2):17&#x2013;20. doi: 10.1016/S0022-510X(01)00569-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00569-X</ArticleId><ArticleId IdType="pubmed">11574101</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2008;273(1-2):67&#x2013;69. doi: 10.1016/j.jns.2008.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.06.025</ArticleId><ArticleId IdType="pubmed">18656208</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenland K, MacNeil J, Seals R, Levey A. Factors affecting survival of patients with neurodegenerative disease. Neuroepidemiology. 2010;35(1):28&#x2013;35. doi: 10.1159/000306055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000306055</ArticleId><ArticleId IdType="pmc">PMC2919432</ArticleId><ArticleId IdType="pubmed">20389122</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Taboada JM, Lopez-Lopez A, Salvado M, Lorenzo L, Garcia C, Mahy N, Rodr&#xed;guez MJ, Gamez J. UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. J Neurol. 2015;262(10):2285&#x2013;2292. doi: 10.1007/s00415-015-7843-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7843-z</ArticleId><ArticleId IdType="pubmed">26162714</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HHG, Westeneng HJ, van der Burgh HK, van Es MA, Bakker LA, van Veenhuijzen K, van Eijk KR, van Eijk RPA, Veldink JH, van den Berg LH. The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis. Ann Neurol. 2020;88(4):796&#x2013;806. doi: 10.1002/ana.25841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25841</ArticleId><ArticleId IdType="pmc">PMC7540607</ArticleId><ArticleId IdType="pubmed">32627229</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetsuka S, Morita M, Iida A, Ikegawa S, Nakano I. ZNF512B gene serves as a prognostic factor in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:122.</Citation></Reference><Reference><Citation>Yu CJ, Wang L, Mao SL, Zhang Y, Song LL, Cai LY, Tao Y. The clinical assessment of amyotrophic lateral sclerosis patients' prognosis by ZNF512B gene, neck flexor muscle power score and body mass index (BMI) BMC Neurol. 2018;18(1):211. doi: 10.1186/s12883-018-1219-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-018-1219-9</ArticleId><ArticleId IdType="pmc">PMC6299516</ArticleId><ArticleId IdType="pubmed">30567526</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Yang B, Wang F, Li K, Zhu Y, Liu B, Ren H, Tian S, Xu Y, Pang A, et al. Association of Single Nucleotide Polymorphism at rs2275294 in the ZNF512B Gene with Prognosis in Amyotrophic Lateral Sclerosis. Neuromolecular Med. 2021;23(2):242&#x2013;246. doi: 10.1007/s12017-020-08634-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-020-08634-y</ArticleId><ArticleId IdType="pubmed">33387304</ArticleId></ArticleIdList></Reference><Reference><Citation>Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, van Es MA, Sapp PC, van Vught PW, McKenna-Yasek DM, Blauw HM, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2009;106(22):9004&#x2013;9009. doi: 10.1073/pnas.0812937106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812937106</ArticleId><ArticleId IdType="pmc">PMC2683883</ArticleId><ArticleId IdType="pubmed">19451621</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Nalls M, Lai SL, Gibbs RJ, Schymick JC, Arepalli S, Hernandez D, van der Brug MP, Johnson JO, Dillman A, et al. Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients. Proc Natl Acad Sci U S A. 2010;107(27):12335&#x2013;12338. doi: 10.1073/pnas.0914079107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0914079107</ArticleId><ArticleId IdType="pmc">PMC2901467</ArticleId><ArticleId IdType="pubmed">20566859</ArticleId></ArticleIdList></Reference><Reference><Citation>Orsetti V, Pegoraro E, Cima V, D'Ascenzo C, Palmieri A, Querin G, Volpe M, Ermani M, Angelini C, Sorar&#xf9; G. Genetic variation in KIFAP3 is associated with an upper motor neuron-predominant phenotype in amyotrophic lateral sclerosis. Neurodegener Dis. 2011;8(6):491&#x2013;495. doi: 10.1159/000327755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000327755</ArticleId><ArticleId IdType="pubmed">21659726</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doormaal PT, Ticozzi N, Gellera C, Ratti A, Taroni F, Chi&#xf2; A, Calvo A, Mora G, Restagno G, Traynor BJ, et al. Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiol Aging. 2014;35(10):2420.e2413&#x2013;2420.e2424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496711</ArticleId><ArticleId IdType="pubmed">24838185</ArticleId></ArticleIdList></Reference><Reference><Citation>Czell D, Sapp PC, Neuwirth C, Weber M, Andersen PM, Brown RH. Further analysis of KIFAP3 gene in ALS patients from Switzerland and Sweden. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3-4):302&#x2013;304. doi: 10.1080/21678421.2017.1280509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1280509</ArticleId><ArticleId IdType="pubmed">28140676</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamez J, Barcel&#xf3; MJ, Mu&#xf1;oz X, Carmona F, Cusc&#xf3; I, Baiget M, Cervera C, Tizzano EF. Survival and respiratory decline are not related to homozygous SMN2 deletions in ALS patients. Neurology. 2002;59(9):1456&#x2013;1460. doi: 10.1212/01.WNL.0000032496.64510.4E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000032496.64510.4E</ArticleId><ArticleId IdType="pubmed">12427907</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Lopez A, Gamez J, Syriani E, Morales M, Salvado M, Rodr&#xed;guez MJ, Mahy N, Vidal-Taboada JM. CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis. PLoS One. 2014;9(5):e96528. doi: 10.1371/journal.pone.0096528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096528</ArticleId><ArticleId IdType="pmc">PMC4013026</ArticleId><ArticleId IdType="pubmed">24806473</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Canosa A, Cammarosano S, Ilardi A, Bertuzzo D, Traynor BJ, Brunetti M, Barberis M, Mora G, et al. Common polymorphisms of chemokine (C-X3-C motif) receptor 1 gene modify amyotrophic lateral sclerosis outcome: A population-based study. Muscle Nerve. 2018;57(2):212&#x2013;216. doi: 10.1002/mus.25653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25653</ArticleId><ArticleId IdType="pmc">PMC5912184</ArticleId><ArticleId IdType="pubmed">28342179</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Taboada JM, Pugliese M, Salvad&#xf3; M, G&#xe1;mez J, Mahy N, Rodr&#xed;guez MJ. K(ATP) Channel Expression and Genetic Polymorphisms Associated with Progression and Survival in Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2018;55(10):7962&#x2013;7972. doi: 10.1007/s12035-018-0970-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0970-7</ArticleId><ArticleId IdType="pubmed">29492846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouzat K, Molinari N, Kantar J, Polge A, Corcia P, Couratier P, Clavelou P, Juntas-Morales R, Pageot N, Lobaccaro JA, et al. Liver X Receptor Genes Variants Modulate ALS Phenotype. Mol Neurobiol. 2018;55(3):1959&#x2013;1965. doi: 10.1007/s12035-017-0453-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0453-2</ArticleId><ArticleId IdType="pubmed">28244008</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Maurer-Stroh S, van Es MA, Van Damme P, van Vught PW, van der Zee J, Serneels S, De Pooter T, Van den Broeck M, et al. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology. 2008;71(4):253&#x2013;259. doi: 10.1212/01.wnl.0000289191.54852.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000289191.54852.75</ArticleId><ArticleId IdType="pubmed">18184915</ArticleId></ArticleIdList></Reference><Reference><Citation>El Oussini H, Bayer H, Scekic-Zahirovic J, Vercruysse P, Sinniger J, Dirrig-Grosch S, Dieterl&#xe9; S, Echaniz-Laguna A, Larmet Y, M&#xfc;ller K, et al. Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis. Acta Neuropathol. 2016;131(3):465&#x2013;480. doi: 10.1007/s00401-016-1534-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1534-4</ArticleId><ArticleId IdType="pubmed">26744351</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, Anderton RS, Mastaglia FL, Flynn LL, Winter SJ, James I, Bedlack R, Hodgetts S, Fletcher S, Wilton SD, et al. Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype. Front Aging Neurosci. 2021;13:658226. doi: 10.3389/fnagi.2021.658226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.658226</ArticleId><ArticleId IdType="pmc">PMC8033025</ArticleId><ArticleId IdType="pubmed">33841129</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Tian D, Li J, Chen L, Tang L, Fan D. The Analysis of Two BDNF Polymorphisms G196A/C270T in Chinese Sporadic Amyotrophic Lateral Sclerosis. Front Aging Neurosci. 2017;9:135. doi: 10.3389/fnagi.2017.00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00135</ArticleId><ArticleId IdType="pmc">PMC5423950</ArticleId><ArticleId IdType="pubmed">28539884</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Fu J, Fan D. The complement C7 variant rs3792646 is associated with amyotrophic lateral sclerosis in a Han Chinese population. Neurobiol Aging. 2021;99:103.e101&#x2013;103.e107. doi: 10.1016/j.neurobiolaging.2020.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.10.012</ArticleId><ArticleId IdType="pubmed">33303220</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, Beleza-Meireles A, Leigh NP, Shaw CE, Al-Chalabi A. Interaction between PON1 and population density in amyotrophic lateral sclerosis. NeuroReport. 2009;20(2):186&#x2013;190. doi: 10.1097/WNR.0b013e32831af220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0b013e32831af220</ArticleId><ArticleId IdType="pubmed">19104460</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Tiloca C, Morelli C, Doretti A, Poletti B, Maderna L, Messina S, Gentilini D, Fogh I, Ratti A, et al. PON1 is a disease modifier gene in amyotrophic lateral sclerosis: association of the Q192R polymorphism with bulbar onset and reduced survival. Neurol Sci. 2019;40(7):1469&#x2013;1473. doi: 10.1007/s10072-019-03834-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03834-2</ArticleId><ArticleId IdType="pubmed">30903418</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauw HM, van Rheenen W, Koppers M, Van Damme P, Waibel S, Lemmens R, van Vught PW, Meyer T, Schulte C, Gasser T, et al. NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21(11):2497&#x2013;2502. doi: 10.1093/hmg/dds064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds064</ArticleId><ArticleId IdType="pubmed">22378146</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Vourc'h P, Nadjar Y, Ribourtout B, Gordon PH, Guettard YO, Camu W, Praline J, Meininger V, Andres CR, et al. Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis. J Neurol Sci. 2011;303(1-2):124&#x2013;127. doi: 10.1016/j.jns.2010.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2010.12.018</ArticleId><ArticleId IdType="pubmed">21276595</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sousa Barros JB, de Faria SK, da Cruz Pereira Bento D, Prado Assun&#xe7;&#xe3;o LD, da Silva Santos R, da Silva Reis AA. Influence of GSTP1 rs1695 polymorphism on survival in male patients' amyotrophic lateral sclerosis: a genetic association study in Brazilian population. Mol Biol Rep. 2022;49(2):1655&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34623592</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Scheffler MD, Smith BN, Parton MJ, Cudkowicz ME, Andersen PM, Hayden DL, Hansen VK, Turner MR, Shaw CE, et al. Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis. Ann Neurol. 2003;54(1):130&#x2013;134. doi: 10.1002/ana.10638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10638</ArticleId><ArticleId IdType="pubmed">12838531</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vught PW, Van Wijk J, Bradley TE, Plasmans D, Jakobs ME, Veldink JH, de Jong JM, Van den Berg LH, Baas F. Ciliary neurotrophic factor null alleles are not a risk factor for Charcot-Marie-Tooth disease, hereditary neuropathy with pressure palsies and amyotrophic lateral sclerosis. Neuromuscul Disord. 2007;17(11-12):964&#x2013;967. doi: 10.1016/j.nmd.2007.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2007.06.006</ArticleId><ArticleId IdType="pubmed">17651970</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Zheng J, Tian S, Chen Y, An R, Zhao Q, Xu Y. HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort. J Neurol Sci. 2017;373:124&#x2013;128. doi: 10.1016/j.jns.2016.12.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.12.055</ArticleId><ArticleId IdType="pubmed">28131168</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisse M, Zwamborn RAJ, van Vugt J, van der Spek R, van Rheenen W, Kenna B, Van Eijk K, Kenna K, Corcia P, Couratier P, et al. The Effect of SMN Gene Dosage on ALS Risk and Disease Severity. Ann Neurol. 2021;89(4):686&#x2013;697. doi: 10.1002/ana.26009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26009</ArticleId><ArticleId IdType="pmc">PMC8048961</ArticleId><ArticleId IdType="pubmed">33389754</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, de Carvalho M, Meyer T, Tysnes OB, Auburger G, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet. 2011;20(9):1697&#x2013;1700. doi: 10.1093/hmg/ddr045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr045</ArticleId><ArticleId IdType="pmc">PMC3071667</ArticleId><ArticleId IdType="pubmed">21292779</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught PW, Thijs V, Dubois B, Matthijs G, van den Berg LH, Robberecht W. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology. 2011;76(24):2066&#x2013;2072. doi: 10.1212/WNL.0b013e31821f445b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821f445b</ArticleId><ArticleId IdType="pubmed">21562247</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud H, Belzil V, Martins S, Sabbagh M, Provencher P, Lacomblez L, Meininger V, Camu W, Dupre N, Dion PA, et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch Neurol. 2011;68(6):739&#x2013;742. doi: 10.1001/archneurol.2011.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.111</ArticleId><ArticleId IdType="pubmed">21670397</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L, Mazzini L, Oggioni GD, Luciano B, Godi M, Brusco A, D'Alfonso S. ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum Genet. 2011;130(4):575&#x2013;580. doi: 10.1007/s00439-011-1000-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-011-1000-2</ArticleId><ArticleId IdType="pubmed">21537950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahut S, Omur O, Uyan O, Agim ZS, Ozoguz A, Parman Y, Deymeer F, Oflazer P, Koc F, Ozcelik H, et al. ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One. 2012;7(8):e42956. doi: 10.1371/journal.pone.0042956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042956</ArticleId><ArticleId IdType="pmc">PMC3423429</ArticleId><ArticleId IdType="pubmed">22916186</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Huang R, Yang Y, Chen K, Song W, Pan P, Li J, Shang HF. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2011;32(10):1925 e1921&#x2013;1925 e1925. doi: 10.1016/j.neurobiolaging.2011.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.05.015</ArticleId><ArticleId IdType="pubmed">21741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD. ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron. 2020;108(5):822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Taylor JP. The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD. Front Mol Neurosci. 2017;10:35. doi: 10.3389/fnmol.2017.00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00035</ArticleId><ArticleId IdType="pmc">PMC5303742</ArticleId><ArticleId IdType="pubmed">28243191</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekhtiari Bidhendi E, Bergh J, Zetterstrom P, Forsberg K, Pakkenberg B, Andersen PM, Marklund SL, Brannstrom T. Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis. Acta Neuropathol. 2018;136(6):939&#x2013;953. doi: 10.1007/s00401-018-1915-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1915-y</ArticleId><ArticleId IdType="pmc">PMC6280858</ArticleId><ArticleId IdType="pubmed">30284034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Lyashchenko AK, Lu L, Nasrabady SE, Elmaleh M, Mendelsohn M, Nemes A, Tapia JC, Mentis GZ, Shneider NA. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun. 2016;7:10465. doi: 10.1038/ncomms10465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10465</ArticleId><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="pubmed">26842965</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7(5):409&#x2013;416. doi: 10.1016/S1474-4422(08)70071-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70071-1</ArticleId><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui R, Tuo M, Li P, Zhou C. Association between TBK1 mutations and risk of amyotrophic lateral sclerosis/frontotemporal dementia spectrum: a meta-analysis. Neurol Sci. 2018;39(5):811&#x2013;820. doi: 10.1007/s10072-018-3246-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3246-0</ArticleId><ArticleId IdType="pubmed">29349657</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes JA, Davies MC, Collins MO. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol Brain. 2017;10(1):5. doi: 10.1186/s13041-017-0287-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0287-x</ArticleId><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao L, He X, Cui B, Zhao F, Zhou C. NEK1 mutations and the risk of amyotrophic lateral sclerosis (ALS): a meta-analysis. Neurol Sci. 2021;42(4):1277&#x2013;1285. doi: 10.1007/s10072-020-05037-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-05037-6</ArticleId><ArticleId IdType="pubmed">33462636</ArticleId></ArticleIdList></Reference><Reference><Citation>Higelin J, Catanese A, Semelink-Sedlacek LL, Oeztuerk S, Lutz AK, Bausinger J, Barbi G, Speit G, Andersen PM, Ludolph AC, et al. NEK1 loss-of-function mutation induces DNA damage accumulation in ALS patient-derived motoneurons. Stem Cell Res. 2018;30:150&#x2013;162. doi: 10.1016/j.scr.2018.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2018.06.005</ArticleId><ArticleId IdType="pubmed">29929116</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin RL, Kenna KP, Vajda A, Byrne S, Bradley DG, Hardiman O. UBQLN2 mutations are not a frequent cause of amyotrophic lateral sclerosis in Ireland. Neurobiol Aging. 2014;35(1):267 e269&#x2013;267 e211. doi: 10.1016/j.neurobiolaging.2013.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.023</ArticleId><ArticleId IdType="pubmed">23973441</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JJ, Cai A, Greenslade JE, Higgins NR, Fan C, Le NTT, Tatman M, Whiteley AM, Prado MA, Dieriks BV, et al. ALS/FTD mutations in UBQLN2 impede autophagy by reducing autophagosome acidification through loss of function. Proc Natl Acad Sci U S A. 2020;117(26):15230&#x2013;15241. doi: 10.1073/pnas.1917371117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1917371117</ArticleId><ArticleId IdType="pmc">PMC7334651</ArticleId><ArticleId IdType="pubmed">32513711</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan C, Jiao B, Xiao T, Hou L, Zhang W, Liu X, Xu J, Tang B, Shen L. Mutations of CCNF gene is rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia from Mainland China. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3-4):265&#x2013;268. doi: 10.1080/21678421.2017.1293111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1293111</ArticleId><ArticleId IdType="pubmed">28281833</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Topp S, Yang S, Smith B, Fifita JA, Warraich ST, Zhang KY, Farrawell N, Vance C, Hu X, et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Commun. 2016;7:11253. doi: 10.1038/ncomms11253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11253</ArticleId><ArticleId IdType="pmc">PMC4835537</ArticleId><ArticleId IdType="pubmed">27080313</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez M, McClain ME, Martinez RA, Snow K, Lipe H, Ravits J, Bird TD, La Spada AR. Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology. 2000;55(4):569&#x2013;572. doi: 10.1212/WNL.55.4.569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.4.569</ArticleId><ArticleId IdType="pubmed">10953195</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MD, Gomes J, Cashman NR, Little J, Krewski D. Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS--a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(8):e105534. doi: 10.1371/journal.pone.0105534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0105534</ArticleId><ArticleId IdType="pmc">PMC4141758</ArticleId><ArticleId IdType="pubmed">25148523</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Mullen B, Heckman MG, Baker MC, DeJesus-Hernandez M, Brown PH, Murray ME, Hsiung GY, Stewart H, Karydas AM, et al. Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol Aging. 2014;35(10):2421.e2413&#x2013;2421.e2427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105839</ArticleId><ArticleId IdType="pubmed">24866401</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, Sidle K, Fratta P, Orrell RW, Hardy J, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol. 2015;14(3):291&#x2013;301. doi: 10.1016/S1474-4422(14)70233-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70233-9</ArticleId><ArticleId IdType="pubmed">25638642</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Lin Z, Chen X, Cao B, Wei Q, Ou R, Zhao B, Song W, Wu Y, Shang HF. Large C9orf72 repeat expansions are seen in Chinese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2016;38:217 e215&#x2013;217 e222. doi: 10.1016/j.neurobiolaging.2015.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.10.021</ArticleId><ArticleId IdType="pubmed">26725464</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Hou Y, Li C, Cao B, Cheng Y, Wei Q, Zhang L, Shang H. Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2021;92(7):688&#x2013;693. doi: 10.1136/jnnp-2020-325701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325701</ArticleId><ArticleId IdType="pubmed">33563800</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Rigo F, Prakash TP, Corey DR. Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs. Nucleic Acid Ther. 2017;27(2):87&#x2013;94. doi: 10.1089/nat.2016.0655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2016.0655</ArticleId><ArticleId IdType="pmc">PMC5372765</ArticleId><ArticleId IdType="pubmed">28005462</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, Petry H, van Deventer SJ, Evers MM, Konstantinova P. Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol Ther Nucleic Acids. 2019;14:593&#x2013;608. doi: 10.1016/j.omtn.2019.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.01.010</ArticleId><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017;88(2):99&#x2013;105. doi: 10.1136/jnnp-2016-313521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313521</ArticleId><ArticleId IdType="pmc">PMC5136332</ArticleId><ArticleId IdType="pubmed">27261500</ArticleId></ArticleIdList></Reference><Reference><Citation>Arisato T, Okubo R, Arata H, Abe K, Fukada K, Sakoda S, Shimizu A, Qin XH, Izumo S, Osame M, et al. Clinical and pathological studies of familial amyotrophic lateral sclerosis (FALS) with SOD1 H46R mutation in large Japanese families. Acta Neuropathol. 2003;106(6):561&#x2013;568. doi: 10.1007/s00401-003-0763-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-003-0763-5</ArticleId><ArticleId IdType="pubmed">14517684</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M, Peikert K, G&#xfc;nther R, van der Kooi AJ, Aronica E, H&#xfc;bers A, Danel V, Corcia P, Pan-Montojo F, Cirak S, et al. Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2019;6(12):2384&#x2013;2394. doi: 10.1002/acn3.50930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50930</ArticleId><ArticleId IdType="pmc">PMC6917314</ArticleId><ArticleId IdType="pubmed">31682085</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, M&#xfc;ller K, Marroquin N, Nordin F, H&#xfc;bers A, Weydt P, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17(1):94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Doronzio PN, Conte A, Marangi G, Martello F, Bisogni G, Meleo E, Colavito D, Del Giudice E, Patanella AK, et al. Novel variants and cellular studies on patients' primary fibroblasts support a role for NEK1 missense variants in ALS pathogenesis. Hum Mol Genet. 2021;30(1):65&#x2013;71. doi: 10.1093/hmg/ddab015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddab015</ArticleId><ArticleId IdType="pubmed">33445179</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Restagno G, Brunetti M, Ossola I, Majounie E, Renton AE, Canosa A, Manera U, Bersano E, Moglia C, et al. UNC13A influences survival in an Italian population-based series. Eur J Neurol. 2012;19:262.</Citation></Reference><Reference><Citation>Diekstra FP, Van Deerlin VM, van Swieten JC, Al-Chalabi A, Ludolph AC, Weishaupt JH, Hardiman O, Landers JE, Brown RH, Jr, van Es MA, et al. C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis. Ann Neurol. 2014;76(1):120&#x2013;133. doi: 10.1002/ana.24198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24198</ArticleId><ArticleId IdType="pmc">PMC4137231</ArticleId><ArticleId IdType="pubmed">24931836</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Jiang H, Wang F, Li S, Wu C, Bao J, Zhu Y, Xu Z, Liu B, Ren H, et al. UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis. Neurol Sci. 2019;40(11):2293&#x2013;2302. doi: 10.1007/s10072-019-03951-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03951-y</ArticleId><ArticleId IdType="pubmed">31201598</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, Bampton A, Lee FCY, Masino L, Qi YA, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, Briner A, Rodriguez CM, Guo C, Akiyama T, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603:124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning P, Yang X, Yang B, Zhao Q, Huang H, An R, Chen Y, Hu F, Xu Z, Xu Y. Meta-analysis of the association between ZNF512B polymorphism rs2275294 and risk of amyotrophic lateral sclerosis. Neurol Sci. 2018;39(7):1261&#x2013;1266. doi: 10.1007/s10072-018-3411-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3411-5</ArticleId><ArticleId IdType="pubmed">29713939</ArticleId></ArticleIdList></Reference><Reference><Citation>Schober A, Peterziel H, von Bartheld CS, Simon H, Krieglstein K, Unsicker K. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. Neurobiol Dis. 2007;25(2):378&#x2013;391. doi: 10.1016/j.nbd.2006.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.10.005</ArticleId><ArticleId IdType="pubmed">17141511</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH, van den Berg LH, Cobben JM, Stulp RP, De Jong JM, Vogels OJ, Baas F, Wokke JH, Scheffer H. Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology. 2001;56(6):749&#x2013;752. doi: 10.1212/WNL.56.6.749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.6.749</ArticleId><ArticleId IdType="pubmed">11274309</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, van Vugt J, Hop PJ, Zwamborn RAJ, de Klein N, Westra HJ, Bakker OB, Deelen P, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636&#x2013;1648. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>